Can mast-cell release of histamine and tryptase drive vascular leak and endothelial inflammation?

The activation of mast cells and the subsequent release of histamine and tryptase are critical drivers of vascular dysfunction and endothelial inflammation. This process involves a complex interplay between pre-formed mediators and the vascular wall, leading to immediate and sustained physiological changes.

Mechanistic pathways

• Vascular Permeability: Histamine acts rapidly on H1 receptors, triggering the p38 MAP kinase, myosin light chain kinase (MLCK), and Rho/ROCK pathways. This results in endothelial cell contraction and the internalization of junctional proteins like VE-cadherin, creating physical gaps that allow for plasma leakage.
• Sustained Dysfunction: Tryptase extends this effect by activating protease-activated receptor-2 (PAR-2). This signaling pathway promotes further junctional instability and amplifies the initial barrier disruption caused by histamine.
• Inflammatory Signaling: Both mediators activate the NF-κB hub within endothelial cells. This induces the expression of adhesion molecules (ICAM-1, VCAM-1) and the secretion of pro-inflammatory cytokines such as IL-6, IL-8, and TNF-α, which recruit leukocytes and sustain a pro-inflammatory state.

Clinical and vascular effects

• Vascular Tone: Histamine significantly alters vascular tone by binding to H2 receptors, inducing acute vasodilation and hypotension. In chronic settings, mast cell activity contributes to vascular remodeling, including smooth muscle proliferation and fibrosis, often seen in conditions like pulmonary arterial hypertension (PAH).
• Biomarkers: Serum tryptase levels exceeding 11.4 ng/mL serve as a reliable clinical marker for significant mast cell degranulation, correlating directly with the severity of vascular leak and hypotensive episodes.

Bottom line

The evidence strongly supports that histamine and tryptase act synergistically to disrupt the endothelial barrier and alter vascular tone. Through H1, H2, and PAR-2 receptor signaling, these mediators drive both acute vascular leakage and long-term inflammatory remodeling, making them central targets in managing systemic inflammatory and allergic conditions.